PLYX Polaryx Therapeutics, Inc. Common Stock
USHealthcareAs of 2026-07-10 16:00
Why PLYX matters now
Polaryx Therapeutics, Inc. Common Stock (PLYX) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.33 with -4.12% on the session and $116.1M in market capitalization; recent performance reads 1-month -24.18% and YTD -93.37%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.5M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.6%.
The latest indexable market news headline is "Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
44.03
P/S
0.00
EV/EBITDA
-16.48
DCF Value
$0.10
FCF Yield
-3.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-166.1%
ROA
-185.0%
ROIC
-190.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.5M | $-0.05 |
| Q4 2025 | $0.00 | $-1.5M | $-0.03 |
| FY 2025 | $0.00 | $-9.0M | $-0.19 |
| Q3 2025 | $0.00 | $-1.4M | $-0.01 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.00
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.